How EGFR Expression Variability Affects Lung Cancer Treatment
Author Information
Author(s): Alsaed Bassel, Lin Linh, Son Jieun, Li Jiaqi, Smolander Johannes, Lopez Timothy, Eser Pinar Ö., Ogino Atsuko, Ambrogio Chiara, Eum Yoonji, Thai Tran, Wang Haiyun, Sutinen Eva, Mutanen Hilma, Duàn Hanna, Bobik Nina, Borenius Kristian, Feng William W., Nabet Behnam, Mustjoki Satu, Laaksonen Sanna, Eschle Benjamin K., Poitras Michael J., Barbie David, Ilonen Ilkka, Gokhale Prafulla, Jänne Pasi A., Haikala Heidi M.
Primary Institution: University of Helsinki
Hypothesis
Does intratumor heterogeneity of EGFR expression contribute to targeted therapy resistance in lung cancer?
Conclusion
EGFR-low cells are more resistant to EGFR inhibitors and contribute to a drug-tolerant tumor microenvironment.
Supporting Evidence
- EGFR-low cells are more invasive and secrete TGFβ, leading to immune suppression.
- Pharmacological induction of EGFR can sensitize resistant cells to treatment.
- EGFR-low cells contribute to a drug-tolerant microenvironment.
- Combination therapies may prevent or reverse intrinsic drug resistance.
Takeaway
Some cancer cells have less EGFR, making them tougher against treatments, which can lead to more problems in fighting the cancer.
Methodology
The study used patient-derived xenograft samples and cell lines to analyze EGFR expression and drug sensitivity.
Potential Biases
Potential bias in sample selection and treatment response assessment.
Limitations
The study primarily focused on a limited number of patient-derived samples and cell lines.
Participant Demographics
Included patients with EGFR-mutant non-small cell lung cancer, varying by ethnicity.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website